NYSE:DPLO - Diplomat Pharmacy Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.30 +0.60 (+4.38 %)
(As of 02/21/2019 05:32 AM ET)
Previous Close$13.70
Today's Range$13.63 - $14.46
52-Week Range$12.30 - $28.74
Volume1.11 million shs
Average Volume490,534 shs
Market Capitalization$1.06 billion
P/E Ratio24.91
Dividend YieldN/A
Beta0.98
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company's primary focus is on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. The company was founded in 1975 and is headquartered in Flint, Michigan.

Receive DPLO News and Ratings via Email

Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
CUSIPN/A
Phone888-720-4450

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.49 billion
Cash Flow$1.9195 per share
Book Value$10.88 per share

Profitability

Net Income$15.51 million

Miscellaneous

Employees2,419
Market Cap$1.06 billion
OptionableOptionable

Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) posted its quarterly earnings results on Tuesday, November, 6th. The company reported $0.01 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.22 by $0.21. The business earned $1.37 billion during the quarter, compared to analyst estimates of $1.42 billion. Diplomat Pharmacy had a net margin of 0.04% and a return on equity of 5.31%. The company's quarterly revenue was up 22.0% on a year-over-year basis. During the same period last year, the firm posted $0.01 earnings per share. View Diplomat Pharmacy's Earnings History.

When is Diplomat Pharmacy's next earnings date?

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Diplomat Pharmacy.

How can I listen to Diplomat Pharmacy's earnings call?

Diplomat Pharmacy will be holding an earnings conference call on Monday, February 25th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8332865805.

What guidance has Diplomat Pharmacy issued on next quarter's earnings?

Diplomat Pharmacy issued an update on its FY 2018 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.5-5.6 billion, compared to the consensus revenue estimate of $5.56 billion.

What price target have analysts set for DPLO?

11 brokers have issued 12-month price objectives for Diplomat Pharmacy's stock. Their predictions range from $15.00 to $33.00. On average, they anticipate Diplomat Pharmacy's share price to reach $21.25 in the next year. This suggests a possible upside of 48.6% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

What is the consensus analysts' recommendation for Diplomat Pharmacy?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

Has Diplomat Pharmacy been receiving favorable news coverage?

News headlines about DPLO stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Diplomat Pharmacy earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the near term.

Who are some of Diplomat Pharmacy's key competitors?

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the folowing people:
  • Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 67)
  • Mr. Atul Kavthekar, CFO & Treasurer
  • Mr. Gary Rice M.B.A., M.S., R.Ph., RPh, MS, MBA, CSP, Exec. VP of Operations (Age 61)
  • Mr. Brian Thomas Griffin, CEO & Chairman (Age 60)
  • Mr. Dave Loschinskey, Chief Information Officer

Who are Diplomat Pharmacy's major shareholders?

Diplomat Pharmacy's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.62%), Dimensional Fund Advisors LP (2.86%), Bank of New York Mellon Corp (2.26%), Northern Trust Corp (1.73%), Rhenman & Partners Asset Management AB (1.62%) and Frontier Capital Management Co. LLC (1.57%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Joel Saban, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

Which major investors are selling Diplomat Pharmacy stock?

DPLO stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, D. E. Shaw & Co. Inc., Bank of America Corp DE, Empirical Capital Management LLC, GW&K Investment Management LLC, Mackay Shields LLC, Barclays PLC and MetLife Investment Advisors LLC. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Jeffrey G Park, Philip R Hagerman and Shawn Tomasello. View Insider Buying and Selling for Diplomat Pharmacy.

Which major investors are buying Diplomat Pharmacy stock?

DPLO stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Advisory Services Network LLC, Dimensional Fund Advisors LP, Royce & Associates LP, BlackRock Inc., Geode Capital Management LLC, Tekla Capital Management LLC and Cambridge Investment Research Advisors Inc.. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

How do I buy shares of Diplomat Pharmacy?

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Diplomat Pharmacy's stock price today?

One share of DPLO stock can currently be purchased for approximately $14.30.

How big of a company is Diplomat Pharmacy?

Diplomat Pharmacy has a market capitalization of $1.06 billion and generates $4.49 billion in revenue each year. The company earns $15.51 million in net income (profit) each year or $0.84 on an earnings per share basis. Diplomat Pharmacy employs 2,419 workers across the globe.

What is Diplomat Pharmacy's official website?

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]


MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  293 (Vote Outperform)
Underperform Votes:  300 (Vote Underperform)
Total Votes:  593
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel